Belgium-based P95, a CRO focused on vaccines, has acquired South Africa’s OnQ Research in a move to expand its global presence in the infectious disease arena.

总部位于比利时的专注于疫苗的首席风险官P95收购了南非的OnQ研究，以扩大其在传染病领域的全球影响力。

Although financial details weren’t disclosed, P95 said the deal should be completed by the end of the year, pending regulatory approvals. P95, which is headquartered in Leuven, Belgium, said in an Oct. 16 release that the combined companies will continue to offer services in disease areas such as oncology, medical devices and cardiology..

尽管财务细节未披露，P95表示，该交易应在年底前完成，等待监管部门的批准。总部位于比利时鲁汶的P95在10月16日的一份新闻稿中表示，合并后的公司将继续在肿瘤学、医疗器械和心脏病学等疾病领域提供服务。。

Both companies have conducted vaccine research for bacterial and viral diseases including influenza, COVID-19, group B strep, respiratory syncytial virus, hepatitis variants and E. coli.

两家公司都对细菌和病毒性疾病进行了疫苗研究，包括流感、新型冠状病毒肺炎、B群链球菌、呼吸道合胞病毒、肝炎变异和大肠杆菌。

“The enhanced geographic footprint of the combined company will accelerate recruitment timelines, while providing our sponsor partners access to a global, diverse patient base,” P95 CEO Thomas Verstraeten said in the release.

P95首席执行官托马斯·弗斯特雷滕（ThomasVerstraeten）在新闻稿中表示：“合并后公司的地理足迹增强，将加快招聘时间表，同时为我们的赞助商合作伙伴提供一个全球多元化的患者群体。”。

“Further, the expansion into Africa for P95’s ongoing real world evidence projects provides a pathway to generate unique insights for both R&D prioritization and the monitoring of public health decision effectiveness.”

“此外，P95正在进行的真实世界证据项目向非洲的扩展提供了一条途径，可以为研发优先次序和公共卫生决策有效性的监测产生独特的见解。”

When the deal is completed, P95, which is a portfolio company of Ampersand Capital Partners, will have operations in more than 30 countries including offices in Europe, Latin America, Asia and Africa.

交易完成后，安培生资本（AmpersandCapitalPartners）投资组合公司P95将在30多个国家开展业务，包括在欧洲、拉丁美洲、亚洲和非洲的办事处。

“Africa has enormous potential to contribute to global infectious disease research, and we believe merging with P95 will help accelerate the continent’s impact on the field,” OnQ’s CEO Catherine Lund said.

OnQ首席执行官凯瑟琳·隆德（CatherineLund）表示：“非洲有巨大潜力为全球传染病研究做出贡献，我们相信与P95融合将有助于加速非洲大陆在该领域的影响。”。

Lund founded the company in 1999. Since then, it has conducted more than 500 trials in 14 African countries.

隆德于1999年成立了这家公司。自那时以来，它在14个非洲国家进行了500多次试验。